請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/25859完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 陳青周(Ching-Chow Chen) | |
| dc.contributor.author | Yuan-Ling Liu | en |
| dc.contributor.author | 劉元琳 | zh_TW |
| dc.date.accessioned | 2021-06-08T06:56:22Z | - |
| dc.date.copyright | 2009-09-15 | |
| dc.date.issued | 2009 | |
| dc.date.submitted | 2009-07-24 | |
| dc.identifier.citation | Abel T, Zukin RS (2008) Epigenetic targets of HDAC inhibition in neurodegenerative and psychiatric disorders. Curr Opin Pharmacol 8(1): 57-64
Agarwal B, Bhendwal S, Halmos B, Moss SF, Ramey WG, Holt PR (1999) Lovastatin augments apoptosis induced by chemotherapeutic agents in colon cancer cells. Clin Cancer Res 5(8): 2223-2229 Armeanu S, Bitzer M, Lauer UM, Venturelli S, Pathil A, Krusch M, Kaiser S, Jobst J, Smirnow I, Wagner A, Steinle A, Salih HR (2005) Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate. Cancer Res 65(14): 6321-6329 Banker DE, Mayer SJ, Li HY, Willman CL, Appelbaum FR, Zager RA (2004) Cholesterol synthesis and import contribute to protective cholesterol increments in acute myeloid leukemia cells. Blood 104(6): 1816-1824 Blum HE (2005) Hepatocellular carcinoma: therapy and prevention. World J Gastroenterol 11(47): 7391-7400 Bolden JE, Peart MJ, Johnstone RW (2006) Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5(9): 769-784 Bowen DG, Walker CM (2005) Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature 436(7053): 946-952 Bressac B, Kew M, Wands J, Ozturk M (1991) Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature 350(6317): 429-431 Caldwell SH, Crespo DM, Kang HS, Al-Osaimi AM (2004) Obesity and hepatocellular carcinoma. Gastroenterology 127(5 Suppl 1): S97-103 Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ (2003) Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348(17): 1625-1638 Cao C, Subhawong T, Albert JM, Kim KW, Geng L, Sekhar KR, Gi YJ, Lu B (2006) Inhibition of mammalian target of rapamycin or apoptotic pathway induces autophagy and radiosensitizes PTEN null prostate cancer cells. Cancer Res 66(20): 10040-10047 Collisson EA, Kleer C, Wu M, De A, Gambhir SS, Merajver SD, Kolodney MS (2003) Atorvastatin prevents RhoC isoprenylation, invasion, and metastasis in human melanoma cells. Mol Cancer Ther 2(10): 941-948 Demierre MF, Higgins PD, Gruber SB, Hawk E, Lippman SM (2005) Statins and cancer prevention. Nat Rev Cancer 5(12): 930-942 Denoyelle C, Vasse M, Korner M, Mishal Z, Ganne F, Vannier JP, Soria J, Soria C (2001) Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study. Carcinogenesis 22(8): 1139-1148 El-Serag HB, Davila JA, Petersen NJ, McGlynn KA (2003) The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 139(10): 817-823 Endo A (1992) The discovery and development of HMG-CoA reductase inhibitors. J Lipid Res 33(11): 1569-1582 Endo A, Kuroda M, Tanzawa K (1976) Competitive inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by ML-236A and ML-236B fungal metabolites, having hypocholesterolemic activity. FEBS Lett 72(2): 323-326 Farazi PA, DePinho RA (2006) Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 6(9): 674-687 Finnin MS, Donigian JR, Cohen A, Richon VM, Rifkind RA, Marks PA, Breslow R, Pavletich NP (1999) Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 401(6749): 188-193 Fraga MF, Ballestar E, Villar-Garea A, Boix-Chornet M, Espada J, Schotta G, Bonaldi T, Haydon C, Ropero S, Petrie K, Iyer NG, Perez-Rosado A, Calvo E, Lopez JA, Cano A, Calasanz MJ, Colomer D, Piris MA, Ahn N, Imhof A, Caldas C, Jenuwein T, Esteller M (2005) Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 37(4): 391-400 Gao L, Cueto MA, Asselbergs F, Atadja P (2002) Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family. J Biol Chem 277(28): 25748-25755 Geng J, Klionsky DJ (2008) The Atg8 and Atg12 ubiquitin-like conjugation systems in macroautophagy. 'Protein modifications: beyond the usual suspects' review series. EMBO Rep 9(9): 859-864 Glaser KB, Li J, Staver MJ, Wei RQ, Albert DH, Davidsen SK (2003) Role of class I and class II histone deacetylases in carcinoma cells using siRNA. Biochem Biophys Res Commun 310(2): 529-536 Gniadecki R (2004) Depletion of membrane cholesterol causes ligand-independent activation of Fas and apoptosis. Biochem Biophys Res Commun 320(1): 165-169 Goodsell DS (2003) The molecular perspective: histone deacetylase. Oncologist 8(4): 389-391 Gozuacik D, Kimchi A (2004) Autophagy as a cell death and tumor suppressor mechanism. Oncogene 23(16): 2891-2906 Greten TF, Korangy F, Manns MP, Malek NP (2009) Molecular therapy for the treatment of hepatocellular carcinoma. Br J Cancer 100(1): 19-23 Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ (1993) The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75(4): 805-816 Hawk E, Viner JL (2005) Statins and cancer--beyond the 'one drug, one disease' model. N Engl J Med 352(21): 2238-2239 Herold C, Ganslmayer M, Ocker M, Hermann M, Geerts A, Hahn EG, Schuppan D (2002) The histone-deacetylase inhibitor Trichostatin A blocks proliferation and triggers apoptotic programs in hepatoma cells. J Hepatol 36(2): 233-240 Hindler K, Cleeland CS, Rivera E, Collard CD (2006) The role of statins in cancer therapy. Oncologist 11(3): 306-315 Hodawadekar SC, Marmorstein R (2007) Chemistry of acetyl transfer by histone modifying enzymes: structure, mechanism and implications for effector design. Oncogene 26(37): 5528-5540 Hoek JB, Pastorino JG (2002) Ethanol, oxidative stress, and cytokine-induced liver cell injury. Alcohol 27(1): 63-68 Holdgate GA, Ward WH, McTaggart F (2003) Molecular mechanism for inhibition of 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase by rosuvastatin. Biochem Soc Trans 31(Pt 3): 528-531 Hoyer-Hansen M, Jaattela M (2007) Connecting endoplasmic reticulum stress to autophagy by unfolded protein response and calcium. Cell Death Differ 14(9): 1576-1582 Hubbert C, Guardiola A, Shao R, Kawaguchi Y, Ito A, Nixon A, Yoshida M, Wang XF, Yao TP (2002) HDAC6 is a microtubule-associated deacetylase. Nature 417(6887): 455-458 Istvan ES, Deisenhofer J (2001) Structural mechanism for statin inhibition of HMG-CoA reductase. Science 292(5519): 1160-1164 Iwata J, Ezaki J, Komatsu M, Yokota S, Ueno T, Tanida I, Chiba T, Tanaka K, Kominami E (2006) Excess peroxisomes are degraded by autophagic machinery in mammals. J Biol Chem 281(7): 4035-4041 Jenuwein T, Allis CD (2001) Translating the histone code. Science 293(5532): 1074-1080 Jiang Z, Zheng X, Lytle RA, Higashikubo R, Rich KM (2004) Lovastatin-induced up-regulation of the BH3-only protein, Bim, and cell death in glioblastoma cells. J Neurochem 89(1): 168-178 Jung SN, Park IJ, Kim MJ, Kang I, Choe W, Kim SS, Ha J (2009) Down-regulation of AMP-activated protein kinase sensitizes DU145 carcinoma to Fas-induced apoptosis via c-FLIP degradation. Exp Cell Res 315(14): 2433-2441 Kawata S, Yamasaki E, Nagase T, Inui Y, Ito N, Matsuda Y, Inada M, Tamura S, Noda S, Imai Y, Matsuzawa Y (2001) Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial. Br J Cancer 84(7): 886-891 Kelly WK, Marks PA (2005) Drug insight: Histone deacetylase inhibitors--development of the new targeted anticancer agent suberoylanilide hydroxamic acid. Nat Clin Pract Oncol 2(3): 150-157 Kew MC (2003) Synergistic interaction between aflatoxin B1 and hepatitis B virus in hepatocarcinogenesis. Liver Int 23(6): 405-409 Kim HS, Hwang JT, Yun H, Chi SG, Lee SJ, Kang I, Yoon KS, Choe WJ, Kim SS, Ha J (2008) Inhibition of AMP-activated protein kinase sensitizes cancer cells to cisplatin-induced apoptosis via hyper-induction of p53. J Biol Chem 283(7): 3731-3742 Klionsky DJ, Cregg JM, Dunn WA, Jr., Emr SD, Sakai Y, Sandoval IV, Sibirny A, Subramani S, Thumm M, Veenhuis M, Ohsumi Y (2003) A unified nomenclature for yeast autophagy-related genes. Dev Cell 5(4): 539-545 Komatsu M, Waguri S, Ueno T, Iwata J, Murata S, Tanida I, Ezaki J, Mizushima N, Ohsumi Y, Uchiyama Y, Kominami E, Tanaka K, Chiba T (2005) Impairment of starvation-induced and constitutive autophagy in Atg7-deficient mice. J Cell Biol 169(3): 425-434 Kondo Y, Kanzawa T, Sawaya R, Kondo S (2005) The role of autophagy in cancer development and response to therapy. Nat Rev Cancer 5(9): 726-734 Kortenhorst MS, Carducci MA, Shabbeer S (2006) Acetylation and histone deacetylase inhibitors in cancer. Cell Oncol 28(5-6): 191-222 Kudo M (2008) Hepatocellular carcinoma 2009 and beyond: from the surveillance to molecular targeted therapy. Oncology 75 Suppl 1: 1-12 Kusama T, Mukai M, Iwasaki T, Tatsuta M, Matsumoto Y, Akedo H, Inoue M, Nakamura H (2002) 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors reduce human pancreatic cancer cell invasion and metastasis. Gastroenterology 122(2): 308-317 Lau WY, Lai EC (2008) Hepatocellular carcinoma: current management and recent advances. Hepatobiliary Pancreat Dis Int 7(3): 237-257 Lavanchy D (2004) Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 11(2): 97-107 Lersch C, Schmelz R, Erdmann J, Hollweck R, Schulte-Frohlinde E, Eckel F, Nader M, Schusdziarra V (2004) Treatment of HCC with pravastatin, octreotide, or gemcitabine--a critical evaluation. Hepatogastroenterology 51(58): 1099-1103 Levine B (2007) Cell biology: autophagy and cancer. Nature 446(7137): 745-747 Levine B, Kroemer G (2008) Autophagy in the pathogenesis of disease. Cell 132(1): 27-42 Li J, Hou N, Faried A, Tsutsumi S, Takeuchi T, Kuwano H (2009) Inhibition of autophagy by 3-MA enhances the effect of 5-FU-induced apoptosis in colon cancer cells. Ann Surg Oncol 16(3): 761-771 Liang XH, Jackson S, Seaman M, Brown K, Kempkes B, Hibshoosh H, Levine B (1999) Induction of autophagy and inhibition of tumorigenesis by beclin 1. Nature 402(6762): 672-676 Lin RJ, Sternsdorf T, Tini M, Evans RM (2001) Transcriptional regulation in acute promyelocytic leukemia. Oncogene 20(49): 7204-7215 Lin YC, Lin JH, Chou CW, Chang YF, Yeh SH, Chen CC (2008) Statins increase p21 through inhibition of histone deacetylase activity and release of promoter-associated HDAC1/2. Cancer Res 68(7): 2375-2383 Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359(4): 378-390 Lu YS, Kashida Y, Kulp SK, Wang YC, Wang D, Hung JH, Tang M, Lin ZZ, Chen TJ, Cheng AL, Chen CS (2007) Efficacy of a novel histone deacetylase inhibitor in murine models of hepatocellular carcinoma. Hepatology 46(4): 1119-1130 Luger K, Mader AW, Richmond RK, Sargent DF, Richmond TJ (1997) Crystal structure of the nucleosome core particle at 2.8 A resolution. Nature 389(6648): 251-260 Luo Z, Saha AK, Xiang X, Ruderman NB (2005) AMPK, the metabolic syndrome and cancer. Trends Pharmacol Sci 26(2): 69-76 Maiuri MC, Zalckvar E, Kimchi A, Kroemer G (2007) Self-eating and self-killing: crosstalk between autophagy and apoptosis. Nat Rev Mol Cell Biol 8(9): 741-752 Marcelli M, Cunningham GR, Haidacher SJ, Padayatty SJ, Sturgis L, Kagan C, Denner L (1998) Caspase-7 is activated during lovastatin-induced apoptosis of the prostate cancer cell line LNCaP. Cancer Res 58(1): 76-83 Marks PA, Richon VM, Rifkind RA (2000) Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 92(15): 1210-1216 Mathew R, Karp CM, Beaudoin B, Vuong N, Chen G, Chen HY, Bray K, Reddy A, Bhanot G, Gelinas C, Dipaola RS, Karantza-Wadsworth V, White E (2009) Autophagy suppresses tumorigenesis through elimination of p62. Cell 137(6): 1062-1075 McClain CJ, Hill DB, Song Z, Deaciuc I, Barve S (2002) Monocyte activation in alcoholic liver disease. Alcohol 27(1): 53-61 Minucci S, Pelicci PG (2006) Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6(1): 38-51 Mizushima N, Levine B, Cuervo AM, Klionsky DJ (2008) Autophagy fights disease through cellular self-digestion. Nature 451(7182): 1069-1075 Mueck AO, Seeger H, Wallwiener D (2003) Effect of statins combined with estradiol on the proliferation of human receptor-positive and receptor-negative breast cancer cells. Menopause 10(4): 332-336 Munshi A, Shafi G, Aliya N, Jyothy A (2009) Histone modifications dictate specific biological readouts. J Genet Genomics 36(2): 75-88 Muratani M, Tansey WP (2003) How the ubiquitin-proteasome system controls transcription. Nat Rev Mol Cell Biol 4(3): 192-201 Nubel T, Dippold W, Kleinert H, Kaina B, Fritz G (2004) Lovastatin inhibits Rho-regulated expression of E-selectin by TNFalpha and attenuates tumor cell adhesion. FASEB J 18(1): 140-142 Ocker M, Alajati A, Ganslmayer M, Zopf S, Luders M, Neureiter D, Hahn EG, Schuppan D, Herold C (2005) The histone-deacetylase inhibitor SAHA potentiates proapoptotic effects of 5-fluorouracil and irinotecan in hepatoma cells. J Cancer Res Clin Oncol 131(6): 385-394 Ogawa K, Yasumura S, Atarashi Y, Minemura M, Miyazaki T, Iwamoto M, Higuchi K, Watanabe A (2004) Sodium butyrate enhances Fas-mediated apoptosis of human hepatoma cells. J Hepatol 40(2): 278-284 Okano H, Shiraki K, Inoue H, Kawakita T, Yamanaka T, Deguchi M, Sugimoto K, Sakai T, Ohmori S, Fujikawa K, Murata K, Nakano T (2003) Cellular FLICE/caspase-8-inhibitory protein as a principal regulator of cell death and survival in human hepatocellular carcinoma. Lab Invest 83(7): 1033-1043 Papeleu P, Loyer P, Vanhaecke T, Elaut G, Geerts A, Guguen-Guillouzo C, Rogiers V (2003) Trichostatin A induces differential cell cycle arrests but does not induce apoptosis in primary cultures of mitogen-stimulated rat hepatocytes. J Hepatol 39(3): 374-382 Paragh G, Foris G, Paragh G, Jr., Seres I, Karanyi Z, Fulop P, Balogh Z, Kosztaczky B, Teichmann F, Kertai P (2005) Different anticancer effects of fluvastatin on primary hepatocellular tumors and metastases in rats. Cancer Lett 222(1): 17-22 Parkin DM, Bray F, Ferlay J, Pisani P (2001) Estimating the world cancer burden: Globocan 2000. Int J Cancer 94(2): 153-156 Pasqualucci L, Bereschenko O, Niu H, Klein U, Basso K, Guglielmino R, Cattoretti G, Dalla-Favera R (2003) Molecular pathogenesis of non-Hodgkin's lymphoma: the role of Bcl-6. Leuk Lymphoma 44 Suppl 3: S5-12 Peart MJ, Tainton KM, Ruefli AA, Dear AE, Sedelies KA, O'Reilly LA, Waterhouse NJ, Trapani JA, Johnstone RW (2003) Novel mechanisms of apoptosis induced by histone deacetylase inhibitors. Cancer Res 63(15): 4460-4471 Pedersen TR, Wilhelmsen L, Faergeman O, Strandberg TE, Thorgeirsson G, Troedsson L, Kristianson J, Berg K, Cook TJ, Haghfelt T, Kjekshus J, Miettinen T, Olsson AG, Pyorala K, Wedel H (2000) Follow-up study of patients randomized in the Scandinavian simvastatin survival study (4S) of cholesterol lowering. Am J Cardiol 86(3): 257-262 Qu X, Yu J, Bhagat G, Furuya N, Hibshoosh H, Troxel A, Rosen J, Eskelinen EL, Mizushima N, Ohsumi Y, Cattoretti G, Levine B (2003) Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene. J Clin Invest 112(12): 1809-1820 Rao S, Lowe M, Herliczek TW, Keyomarsi K (1998) Lovastatin mediated G1 arrest in normal and tumor breast cells is through inhibition of CDK2 activity and redistribution of p21 and p27, independent of p53. Oncogene 17(18): 2393-2402 Ray KK, Cannon CP (2005) The potential relevance of the multiple lipid-independent (pleiotropic) effects of statins in the management of acute coronary syndromes. J Am Coll Cardiol 46(8): 1425-1433 Reggiori F, Shintani T, Nair U, Klionsky DJ (2005) Atg9 cycles between mitochondria and the pre-autophagosomal structure in yeasts. Autophagy 1(2): 101-109 Reggiori F, Tucker KA, Stromhaug PE, Klionsky DJ (2004) The Atg1-Atg13 complex regulates Atg9 and Atg23 retrieval transport from the pre-autophagosomal structure. Dev Cell 6(1): 79-90 Roberts LR, Gores GJ (2005) Hepatocellular carcinoma: molecular pathways and new therapeutic targets. Semin Liver Dis 25(2): 212-225 Sasazawa Y, Futamura Y, Tashiro E, Imoto M (2009) Vacuolar H(+)-ATPase inhibitors overcome Bcl-xL-mediated chemoresistance through restoration of a caspase-independent apoptotic pathway. Cancer Sci Sato K, Tsuchihara K, Fujii S, Sugiyama M, Goya T, Atomi Y, Ueno T, Ochiai A, Esumi H (2007) Autophagy is activated in colorectal cancer cells and contributes to the tolerance to nutrient deprivation. Cancer Res 67(20): 9677-9684 Schartl M, Bocksch W, Koschyk DH, Voelker W, Karsch KR, Kreuzer J, Hausmann D, Beckmann S, Gross M (2001) Use of intravascular ultrasound to compare effects of different strategies of lipid-lowering therapy on plaque volume and composition in patients with coronary artery disease. Circulation 104(4): 387-392 Shao Y, Gao Z, Marks PA, Jiang X (2004) Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. Proc Natl Acad Sci U S A 101(52): 18030-18035 Shin EC, Shin JS, Park JH, Kim JJ, Kim H, Kim SJ (1998) Expression of Fas-related genes in human hepatocellular carcinomas. Cancer Lett 134(2): 155-162 Song G, Ouyang G, Bao S (2005) The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med 9(1): 59-71 Sparmann A, van Lohuizen M (2006) Polycomb silencers control cell fate, development and cancer. Nat Rev Cancer 6(11): 846-856 Sutheesophon K, Nishimura N, Kobayashi Y, Furukawa Y, Kawano M, Itoh K, Kano Y, Ishii H (2005) Involvement of the tumor necrosis factor (TNF)/TNF receptor system in leukemic cell apoptosis induced by histone deacetylase inhibitor depsipeptide (FK228). J Cell Physiol 203(2): 387-397 Svechnikova I, Gray SG, Kundrotiene J, Ponthan F, Kogner P, Ekstrom TJ (2003) Apoptosis and tumor remission in liver tumor xenografts by 4-phenylbutyrate. Int J Oncol 22(3): 579-588 Thiagalingam S, Cheng KH, Lee HJ, Mineva N, Thiagalingam A, Ponte JF (2003) Histone deacetylases: unique players in shaping the epigenetic histone code. Ann N Y Acad Sci 983: 84-100 Urabe Y, Nouso K, Higashi T, Nakatsukasa H, Hino N, Ashida K, Kinugasa N, Yoshida K, Uematsu S, Tsuji T (1996) Telomere length in human liver diseases. Liver 16(5): 293-297 Waddington CH (1942) The epigenotype. Endeavour 1: 18-20 Wang C, Gale M, Jr., Keller BC, Huang H, Brown MS, Goldstein JL, Ye J (2005) Identification of FBL2 as a geranylgeranylated cellular protein required for hepatitis C virus RNA replication. Mol Cell 18(4): 425-434 Wang IK, Lin-Shiau SY, Lin JK (2000) Induction of apoptosis by lovastatin through activation of caspase-3 and DNase II in leukaemia HL-60 cells. Pharmacol Toxicol 86(2): 83-91 Weinstein-Oppenheimer CR, Henriquez-Roldan CF, Davis JM, Navolanic PM, Saleh OA, Steelman LS, Franklin RA, Robinson PJ, McMahon M, McCubrey JA (2001) Role of the Raf signal transduction cascade in the in vitro resistance to the anticancer drug doxorubicin. Clin Cancer Res 7(9): 2898-2907 Weis M, Heeschen C, Glassford AJ, Cooke JP (2002) Statins have biphasic effects on angiogenesis. Circulation 105(6): 739-745 Wennerberg K, Rossman KL, Der CJ (2005) The Ras superfamily at a glance. Journal of Cell Science 118(pt5): 843-846 Xie Z, Klionsky DJ (2007) Autophagosome formation: core machinery and adaptations. Nat Cell Biol 9(10): 1102-1109 Xu WS, Parmigiani RB, Marks PA (2007) Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 26(37): 5541-5552 Yin XM, Ding WX, Gao W (2008) Autophagy in the liver. Hepatology 47(5): 1773-1785 | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/25859 | - |
| dc.description.abstract | 肝癌是世界上常見的癌症，發生率排名第五，而致死率則高居第三，但是卻遲遲未出現有效的藥物治療。Statins 在臨床前實驗中，發現其對於癌症的預防具有發展潛力，在我們的研究中，證明了其發展為肝癌治療用藥的潛力。我們發現，atorvastatin在試管內或活體實驗中可抑制肝癌細胞株的生長，在皮下腫瘤的模式，利用電子顯微鏡觀察其細胞型態的改變，裸鼠餵食atorvastatin能讓其皮下移植的腫瘤有自體吞噬的現象。配合西方點墨法確認有給予atorvastatin的腫瘤細胞中LC3-II有增加現象。Atorvastatin 藉由活化AMPK抑制mTOR，使肝癌細胞產生自體吞噬現象，除了自體吞噬外，atorvastatin也引起了細胞凋零現象。合併atorvastatin以及自體吞噬抑制劑（3-MA或baf A1），可抑制atorvastatin所產生的自體吞噬，增加其對癌細胞的毒殺作用以及細胞凋零之現象。因此，atorvastatin在肝癌細胞所引起的自體吞噬現象，可能是扮演細胞保護並對抗細胞凋零的角色，若合併自體吞噬抑制劑，可加強atorvastatin對肝癌的治療效果。本研究還使用HDAC inhibitor---SAHA進行實驗，同樣看到其抑制肝癌細胞株之生長，以及自體吞噬和細胞凋零現象。然而，合併SAHA和自體吞噬抑制劑，卻降低SAHA對於肝癌細胞的毒性，因此SAHA所引發之自體吞噬現象，可能是走向細胞死亡。
本研究證明了atorvastatin 以及SAHA使用於肝癌治療的潛力，這兩種藥物所產生之自體吞噬現象，為治療肝癌的重要標的。 | zh_TW |
| dc.description.abstract | Hepatocellular carcinoma (HCC) is the fifth most common cancer and the third leading cause of cancer death worldwide. Drug treatments for HCC have been largely unsuccessful. Statins show promise for cancer prevention in preclinical and randomized controlled studies. This study investigated the potential of atorvastatin as a treatment for HCC. Atorvastatin inhibited cell growth of Huh7 cells in vitro and in vivo. In xenograft model, morphologic examinations by electron microscopy revealed atorvastatin-induced autophagosome formation. Increase in LC3-II and beclin-1 were also observed by Western blotting. Atorvastatin induced autophagy in an AMPK/mTOR pathway, and also induced apoptosis in Huh7 cells. Both of them were involved in atorvastatin-induced cell death. The atorvastatin-induced cell death and apoptosis could be enhanced by autophagy inhibitors, 3-MA and baf A1. Thus, atorvastatin induced autophagy might lead to cell survival and anti-apoptosis. We also found that a HDAC inhibitor, SAHA, induced autophagy and apoptosis. However, SAHA-induced cell death could be reversed by autophagy inhibitors or using Atg5-/- MEFs, indicating that SAHA induced autophagic cell death. Taken together, our results show the potential of atorvastatin and SAHA as a treatment for HCC. In addition, the pharmacological targeting of autophagy provides promise for the management of cancer therapy. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-08T06:56:22Z (GMT). No. of bitstreams: 1 ntu-98-R96443020-1.pdf: 5356605 bytes, checksum: 7462f6a1dcdd2912095435ffd06f6c8b (MD5) Previous issue date: 2009 | en |
| dc.description.tableofcontents | Abbreviation ----------------------------------- 4
中文摘要 ----------------------------------- 5 Abstract in English ---------------------------- 6 I. Introduction ------------------------------- 7 II. Materials and Methods ---------------------- 46 III.Result ------------------------------------- 50 IV. Discussion --------------------------------- 79 V. Reference ---------------------------------- 83 | |
| dc.language.iso | en | |
| dc.subject | 降膽固醇藥物 | zh_TW |
| dc.subject | 自體吞噬 | zh_TW |
| dc.subject | 肝癌 | zh_TW |
| dc.subject | 組織蛋白去乙醯酶 | zh_TW |
| dc.subject | autophagy | en |
| dc.subject | hepatoma | en |
| dc.subject | HDACi | en |
| dc.subject | statin | en |
| dc.title | 肝癌細胞中自體吞噬現象之探討 | zh_TW |
| dc.title | Investigation of Autophagy in HCC | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 97-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 吳明賢,黃偉邦 | |
| dc.subject.keyword | 肝癌,自體吞噬,降膽固醇藥物,組織蛋白去乙醯酶, | zh_TW |
| dc.subject.keyword | hepatoma,autophagy,statin,HDACi, | en |
| dc.relation.page | 93 | |
| dc.rights.note | 未授權 | |
| dc.date.accepted | 2009-07-24 | |
| dc.contributor.author-college | 醫學院 | zh_TW |
| dc.contributor.author-dept | 藥理學研究所 | zh_TW |
| 顯示於系所單位： | 藥理學科所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-98-1.pdf 未授權公開取用 | 5.23 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。